このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.

2019年1月9日 更新者:Stine Estrup、Zealand University Hospital

PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit. A Prospective Cohort Study.

This study investigates a possible relationship between disturbance of the cyclic expression of ten different clock genes and development of delirium in patients admitted to an intensive care unit

It also investigates a possible relationship between disturbance of the cyclic expression of melatonin and development of delirium in patients admitted to an intensive care unit.

Finally a possible relationship between genetic differences in the PER3 gene and development of delirium is investigated.

調査の概要

状態

引きこもった

条件

詳細な説明

An increasing number of patients are treated at ICUs worldwide. The majority of these patients survive critical illness and are discharged from hospital. In recent decades, improved therapy and survival at ICUs has increased focus on long term outcomes and post-ICU rehabilitation. Both physical and mental problems following admission for ICU therapy can be found for years after discharge. It is therefore important to discover factors that may have a significant impact for a worsened outcome, in order to prevent and treat these impairments.

Cognitive deficiencies may affect large proportions of the post intensive care population and mild cognitive impairment was demonstrated for up to 40% of the patients when evaluated three months after discharge. Recovery was slow and at one year follow up, 25% of the patients still showed impairment comparable to mild traumatic brain injury.

The presence of delirium during ICU stay has been associated with a worsened cognitive outcome at both 3 and 12 months follow up. Both patient's global cognition and especially executive function was impaired. Furthermore, a longer duration of the delirium period was associated with a poorer cognitive function. Incidence of delirium has also shown association to higher mortality rates and a longer hospital stay when compared to patients without delirium. In previous studies, the second day of admission has had the highest incidence of delirium.

Alterations in sleep architecture with a more shallow sleep and disruptions of the sleep wake cycle, is common in both ICU patients and patients with delirium. Sleep deprivation is often seen in delirious patients, and consequently, it has been suggested to be a risk factor for development of delirium.

The circadian rhythm is an inborn cycle of biological activity based on 24 hour intervals, and the rhythmicity interacts with sleep homeostasis in order to regulate sleep-wake cycles of individuals. In humans, the circadian rhythm is controlled by the suprachiasmatic nucleus (SCN) (the circadian clock) mediating melatonin secretion from the pineal gland to regulate the sleep-wake cycle. A number of factors, especially daylight, influence the SCN.

When blue light (460-480 nm wavelengths) reaches the retina and excites photoreceptors, it communicates with the pineal gland and secretion of melatonin is reduced to a minimum. Melatonin is secreted at night when blue light is absent and promotes sleep by activation of melatonin receptors. Melatonin secretion also interacts with a number of body functions, including core body temperature and the cardiac and immune systems. It is one of the key molecules in circadian rhythmicity. The circadian rhythm is not only affected by light, but is also synchronized by other factors, including shift work, artificial light exposure and exercise.

A number of genetic markers known as clock genes play a major role in the circadian control of different processes in the body. These genes may determine an individual's chronotype (morningness/eveningness), sensitivity to sleep disturbance and sleep deprivation, but much of their significance and function is still unknown.

A group of genes named PERIOD genes are shown to be involved in determining individual sleep wake regulation. PERIOD3 (PER3) is found in three subtypes: PER3 4/4, PER3 4/5 and PER3 5/5. The numbers refer to a variable number of tandem repeat polymorphism where a motif of 54 nucleotides is repeated for 4 or 5 U. Studies in large populations have shown 10% of individuals to be homozygous for the 5'-variation, 50% for the 4'-variation and 40% to be heterozygous.

Patients with homozygosity of the long allele (PER35/5) have more slow wave sleep and longer sleep duration compared to the other sub-types. Though no difference in melatonin or cortisol levels where seen, the two types reacted very differently to sleep deprivation. PER35/5 individuals performed poorly on a variety of cognitive tests compared to PER34/4. This information might help to identify subgroups of patients especially sensitive to development of delirium.

A recent study explored the relationship between PER3 genotype and postoperative cognitive dysfunction and did not find an association. The distribution of PER3 subtypes were as expected from previous studies. However, a possible association between PER 3 genotypes and cognitive dysfunction has never been investigated in ICU patients.

A number of other genes are involved in the circadian rhythm. These genes are expressed in a rhythmic manner following the natural light/dark cycle.

In healthy subjects, severely disturbed expression of the clock genes Clock, Cry1-2, Per1-3, Rorα, Bmal1, Rev-erb and CSNK1ε has been demonstrated after injection of endotoxin.

In septic ICU patients, a desynchronised expression of Cry-1 and Per-2 has been demonstrated. This disturbance was linked to secretion of proinflammatory cytokines as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6).

The implication of the above is that if a disturbed circadian rhythm can be demonstrated to be associated with patients in delirium, we might in the future be able to identify patients with a higher risk of developing delirium - even in comatose or heavily sedated patients. Something which is not possible with the current diagnostic methods.

In this study, we therefore wish to investigate the relationship between PER3 gene polymorphism and incidence of delirium. This may help to identify patient groups at a higher risk of developing delirium and potentially prevent or treat these patients at an earlier stage.

The other objective is to identify differences in melatonin and cyclic gene expression in delirious patients, compared to other critically ill patients. This may be a new perspective for the diagnosis of delirium in heavily sedated patients.

研究の種類

観察的

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Køge、デンマーク、4600
        • Zealand University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adult patients admitted to the ICU at Køge Hospital in the study period

説明

Inclusion Criteria:

  • Patients >18 years of age admitted to the ICU at Køge Hospital in the study period

Exclusion Criteria:

  • Not able to speak or understand Danish
  • Melatonin (ATC N05CH01) or melatonin agonist (ATC N06AX) treatment prior to admission
  • Known insomnia (daily hypnotic (ATC N05C) consumption or known sleep disorder)
  • Patients discharged from the ICU during the test period (time from first to last blood sample)
  • Patients who die during the test period
  • Patients transferred to another hospital during ICU stay

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Clock gene expression
時間枠:24 hours
Association between expression of clock genes (Clock, Cry1-2, Per1-3, Rorα, Bmal1, Rev-erb and CSNK1ε) (measured at 6am, 10am, 2pm, 6pm, 10pm and 2am) and incidence of delirium at the ICU
24 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Melatonin secretion
時間枠:24 hours
Association between secretion of melatonin at 6am, 10am, 2pm, 6pm, 10pm and 2am. Cosinor curve analysis (mesor, amplitude and acrophase) and incidence of delirium
24 hours
PER3 subtype
時間枠:24 hours
Association between PER3 subtype determination at 6am (PER3 4/4, PER3 4/5 and PER3 5/5) and incidence and duration of delirium
24 hours
Delirium type
時間枠:24 hours
Delirium type (hypoactive/hyperactive/mixed) associated to PER3 and expression pattern of clock genes and melatonin secretion
24 hours
Demographic variables
時間枠:24 hours
Age, gender, weight at admission associated to PER3 and expression pattern of clock genes and melatonin secretion
24 hours
Sedation
時間枠:24 hours
Infusion of propofol, dexmedetomidine, midazolam, sufentanil, remifentanil associated to PER3 and expression pattern of clock genes and melatonin secretion
24 hours
Disease severity
時間枠:24 hours
SAPS II score at admission associated to PER3 and expression pattern of clock genes and melatonin secretion
24 hours
Admission type
時間枠:24 hours
Type of admission (medical/acute surgical/elective surgical) associated to PER3 and expression pattern of clock genes and melatonin secretion
24 hours
Length of stay
時間枠:Up to 6 months
Length of stay at ICU and hospital associated to PER3 and expression pattern of clock genes and melatonin secretion
Up to 6 months
Number of ventilator days
時間枠:Up to 6 months
Number of ventilator days at ICU and hospital associated to PER3 and expression pattern of clock genes and melatonin secretion
Up to 6 months
ICU delirium
時間枠:Up to 6 months
Delirium defined as positive CAM-ICU or treatment with antipsychotics
Up to 6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Ole Mathiesen, MD, PhD、Køge Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (予想される)

2018年9月1日

一次修了 (予想される)

2020年9月1日

研究の完了 (予想される)

2020年9月1日

試験登録日

最初に提出

2016年2月1日

QC基準を満たした最初の提出物

2016年2月1日

最初の投稿 (見積もり)

2016年2月4日

学習記録の更新

投稿された最後の更新 (実際)

2019年1月10日

QC基準を満たした最後の更新が送信されました

2019年1月9日

最終確認日

2019年1月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • SE 2-16

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

3
購読する